Warning: The NCBI web site requires JavaScript to function. more...
Interleukin-6: discovery of a pleiotropic cytokine.
Kishimoto T.
Arthritis Res Ther. 2006;8 Suppl 2:S2. Epub 2006 Jul 28. Review.
Related citations
IL-6: from laboratory to bedside.
Clin Rev Allergy Immunol. 2005 Jun;28(3):177-86. Review.
IL-6: from its discovery to clinical applications.
Int Immunol. 2010 May;22(5):347-52. Epub 2010 Apr 21. Review.
Inhibition of IL-6 for the treatment of inflammatory diseases.
Nishimoto N, Kishimoto T.
Curr Opin Pharmacol. 2004 Aug;4(4):386-91. Review.
Interleukin 6: from bench to bedside.
Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26. Review. Erratum in: Nat Clin Pract Rheumatol. 2006 Dec;2(12):691.
Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
Nishimoto N.
Clin Rev Allergy Immunol. 2005 Jun;28(3):221-30. Review.
Interleukin-6: from basic science to medicine--40 years in immunology.
Annu Rev Immunol. 2005;23:1-21. Review.
[Clinical application of interleukin-6 receptor antibody].
Nishimoto N, Shima Y, Sasai M, Danno N, Yoshizaki K.
Nihon Rinsho Meneki Gakkai Kaishi. 1997 Apr;20(2):87-94. Review. Japanese.
Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
Nishimoto N, Kishimoto T, Yoshizaki K.
Ann Rheum Dis. 2000 Nov;59 Suppl 1:i21-7. Review.
Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir.
Hirano T.
Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(7):717-30. Review.
Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.
Hsu SM, Xie SS, Hsu PL, Waldron JA Jr.
Am J Pathol. 1992 Jul;141(1):129-38.
Interleukin-6: historical background, genetics and biological significance.
Wolvekamp MC, Marquet RL.
Immunol Lett. 1990 Mar-Apr;24(1):1-9. Review.
Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A, Arai K.
Oncologist. 1996;1(5):337-339.
Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
Nishi J, Maruyama I.
Leuk Lymphoma. 2000 Jul;38(3-4):387-94. Review.
Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K.
Drugs Today (Barc). 2006 Sep;42(9):559-76. Review.
Interleukin-6 and chronic inflammation.
Gabay C.
Arthritis Res Ther. 2006;8 Suppl 2:S3. Epub 2006 Jul 28. Review.
Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.
Arthritis Res. 1999;1(1):81-91. Epub 1999 Oct 26.
[New therapeutic strategy for autoimmune diseases. 3) Treatment of autoimmune diseases by cytokine signal transduction inhibition].
Nishimoto N, Yoshizaki K, Kishimoto T.
Nihon Naika Gakkai Zasshi. 1998 Sep 10;87(9):1745-50. Review. Japanese. No abstract available.
Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y.
Biol Pharm Bull. 2007 Nov;30(11):2001-6. Review.
Interleukin-6: structure-function relationships.
Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD.
Protein Sci. 1997 May;6(5):929-55. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on